


PHARMACEUTICAL 2020

Celsion CORP Rank 176 of 362







PHARMACEUTICAL 2020

Celsion CORP Rank 176 of 362



The relative strengths and weaknesses of Celsion CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Celsion CORP compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 136% points. The greatest weakness of Celsion CORP is the variable Revenues, reducing the Economic Capital Ratio by 56% points.

The company's Economic Capital Ratio, given in the ranking table, is -169%, being 134% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	16,235
Cost of Goods Sold	0
Intangible Assets	2,317
Liabilities, Current	7,894
Liabilities, Non-Current	1,144
Other Assets	19,321
Other Compr. Net Income	13
Other Expenses	-1,816
Other Liabilities	14,681
Other Net Income	1,897
Property and Equipment	405
Research and Development	13,065
Revenues	500
Selling, General and Administrative Expense	8,000

Output Variable	Value in 1000 USD
Assets	38,278
Liabilities	23,719
Expenses	19,249
Stockholders Equity	14,559
Net Income	-16,852
Comprehensive Net Income	-16,845
Economic Capital Ratio	-169%